Oral GLP-1 Uptake Is Rising. What Do Prescription Counts Actually Show?

A November 6 report in Healio has renewed attention on a question that matters to clinics watching oral GLP-1 medicines: are tablets bringing new people into treatment, or mainly moving people away from injections? The answer depends partly on what a dataset can see. A national pharmacy analysis and a separate electronic health record study both describe rapid early uptake, but neither turns prescription growth into proof of clinical benefit or a guaranteed increase in a particular clinic's patients. [3][1][4]

The new coverage and the older research

Healio's November 6 story discusses work by Yara Jelwan and colleagues in Annals of Internal Medicine. The journal identifies the paper as published October 13, 2026. The November news coverage is not the study's publication date, and its data do not run through November. The study used national pharmacy prescription data through June 2026. That distinction matters in a market where additional products and access arrangements have appeared since the measurement window closed. [3][4][5]

According to the American College of Physicians' research release, the analysis found rapid uptake of oral semaglutide for weight management after its January launch and rising overall treatment use without a reduction in injectable semaglutide prescriptions. Medscape's account specifies that the pill exceeded 100,000 monthly new prescriptions within two months. That is a monthly prescription measure, not a count of all unique patients treated or a cumulative total over the entire year. [4][5]

The Annals publisher page provides the article identity and research-data source, but the accessible excerpt does not show the full methods and results. The numerical description here is therefore attributed to the research release and Medscape's report, rather than presented as an independent reanalysis of the underlying IQVIA data. Those data are identified by the journal as its National Prescription Audit product. [4][5][2]

A second study can see prior treatment

A separate October 7 JAMA Network Open study provides a different view. It used deidentified Epic Cosmos electronic health records to examine adults eligible for obesity management medication without type 2 diabetes. Its observation window ran from December 22, 2025, through March 15, 2026. Researchers identified 148,792 people initiating oral semaglutide within a cohort of 47,894,786 eligible adults. [1]

In that analysis, 53.0% of oral semaglutide initiators had no recorded GLP-1 receptor agonist use during the preceding twelve months. The remaining 47.0% had prior recorded use. The authors interpret the pattern as suggesting both expansion to new users and switching from existing therapies. It is not evidence that every oral prescription represented someone who would otherwise have received no treatment. [1]

The product definition also matters. Of the oral semaglutide initiators, 87.6% received oral Wegovy and 12.4% received Rybelsus. Calling the entire group oral Wegovy users would erase part of the study population. Prescribing indications were unavailable in the records, although the researchers excluded adults with type 2 diabetes to reduce potential indication misclassification. [1]

A rising line is not a patient journey

The JAMA study defined a new initiation as a first prescription for the study drug with no prescription for that same drug during the preceding twelve months. That is different from being new to the whole drug class. Someone starting a different GLP-1 medicine can meet the first definition while already having prior exposure to another one. The separate class-naive analysis helps keep those questions apart. [1]

Weekly oral semaglutide initiation rose quickly and approached injectable semaglutide during the early window. Tirzepatide retained the highest weekly initiation rate throughout the period. Among adults without prior class use, oral semaglutide initiation remained below injectable semaglutide. These details are more informative than treating an early uptake headline as a declaration that tablets have overtaken every injectable. [1]

The national pharmacy analysis addresses a different question with aggregate monthly filled new prescriptions. As Medscape notes, aggregated data could not track individual patients or switching. The dataset also did not capture compounded semaglutide or tirzepatide and lacked details on coverage, denied claims and cash payments. An increase in one branded channel is therefore not a complete census of the whole treatment market. [5]

What can and cannot explain the growth

In Healio's interview, coauthor Michael Blaha described the oral option as appearing to grow the overall treatment pool rather than simply taking from injectable use. The article discusses possible explanations including injection preferences, cost, marketing and product availability. Those are proposed explanations, not factors isolated by a randomized experiment. [3]

The JAMA authors are explicit that their study was descriptive, was not designed to assess causal effects and did not adjust for potential confounding or other biases. Its limitations also include delays in data availability and missing prescriptions outside participating Epic health systems, including some online and direct-to-consumer channels. A national-looking dataset can still have important blind spots. [1]

Prescription orders in an electronic record may not reflect actual dispensing or use. A filled prescription, in turn, does not establish continued use months later. Neither measure should be silently substituted for adherence, persistence, clinical outcomes or the number of people retained by a practice. The JAMA authors call for longer-term research on those questions. [1]

How a clinic can read the evidence

The business value of these studies is a clearer set of measurement questions. A practice can distinguish an inquiry, a prescription order, a fill and a later follow-up instead of treating all four as the same event. That is an operational interpretation, not a treatment recommendation or a prediction of how much demand the practice will receive.

Similarly, a new patient to a clinic is not necessarily new to GLP-1 treatment. A new prescription for a product is not necessarily a new user of the drug class. A market comparison that mixes those definitions can make switching look like expansion, or obscure genuine new participation. The two studies show why the denominator and the observation window belong beside the headline. [1][5]

The evidence supports a measured conclusion: oral semaglutide had rapid early uptake in the populations and channels examined, while injectable use continued. How much that pattern persists, which patients it reaches and what happens after the first prescription require further observation. A clinic's own demand and retention cannot be read directly from those national totals. [3][1][4]

A new prescription for a product is not necessarily a new patient to the drug class.

What it means for a clinic: Treat early oral GLP-1 uptake as a market signal with defined limits. Ask whether a number counts orders, fills or people; whether prior treatment is visible; and which channels the dataset misses. The research suggests room for both new participation and switching, without establishing that tablets caused the growth, that every prescription was filled, or that a particular practice will see the same pattern. [1][5]